Affimed (NASDAQ:AFMD) Short Interest Down 12.3% in December

Affimed (NASDAQ:AFMD) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 742,900 shares, a drop of 12.3% from the December 15th total of 846,900 shares. Based on an average trading volume of 291,200 shares, the short-interest ratio is presently 2.6 days. Approximately 5.7% of the shares of the stock are sold short.

Affimed Price Performance

Shares of Affimed stock opened at $1.15 on Friday. Affimed has a twelve month low of $1.03 and a twelve month high of $8.95. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average price of $2.05 and a 200 day moving average price of $3.37.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company decreased their price target on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Stifel Nicolaus decreased their target price on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Institutional Investors Weigh In On Affimed

Several institutional investors and hedge funds have recently modified their holdings of the stock. Choreo LLC acquired a new position in shares of Affimed during the second quarter worth $54,000. Intellectus Partners LLC boosted its position in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after buying an additional 10,250 shares during the last quarter. FMR LLC boosted its position in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares during the last quarter. Point72 Asset Management L.P. grew its stake in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Affimed during the third quarter worth about $44,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.